SCHEMBL16150288

SCHEMBL16150288

CCOc1ccc(C)nc1C(=O)N1C[C@H]2C[C@@H](Nc3ncc(C(F)(F)F)cn3)[C@@H]1C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 18/20 1.00
HCRTR1 O43613 16/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16157685 1.00 HCRTR2 (1.00) HCRTR2HCRTR1
SCHEMBL16150287 1.00 HCRTR2 (1.00) HCRTR2HCRTR1
SCHEMBL29912225 1.00 HCRTR2 (1.00) HCRTR2HCRTR1
SCHEMBL18699581 0.90 HCRTR2 (0.82) HCRTR2HCRTR1
SCHEMBL16040295 0.83 HCRTR2 (1.00) HCRTR2HCRTR1
SCHEMBL30419957 0.83 HCRTR2 (1.00) HCRTR2HCRTR1
SCHEMBL16091960 0.83 HCRTR2 (1.00) HCRTR2HCRTR1
SCHEMBL16044129 0.83 HCRTR2 (1.00) HCRTR2HCRTR1
SCHEMBL16044125 0.83 HCRTR2 (1.00) HCRTR2HCRTR1
SCHEMBL21374853 0.83 HCRTR2 (0.70) HCRTR2HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4272824-A2 SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-11-08 EP disclosed
EP-3622956-B9 SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-09-27 EP disclosed
EP-3622956-B1 SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-06-07 EP disclosed
EP-3622956-A1 SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2020-03-18 EP disclosed
EP-3363438-B1 SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-09-18 EP disclosed
US-10183953-B2 Substituted 2-azabicycles and their use as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2019-01-22 US disclosed
EP-3363438-A1 SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2018-08-22 EP disclosed
US-20170204096-A1 Substituted 2-Azabicycles And Their Use As Orexin Receptor Modulators JANSSEN PHARMACEUTICA NV (BE) 2017-07-20 US disclosed
US-9611277-B2 Substituted 2-azabicycles and their use as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2017-04-04 US disclosed
US-20160052939-A1 SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-02-25 US disclosed
EP-2970314-A1 SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS Janssen Pharmaceutica, N.V. (BE) 2016-01-20 EP disclosed
WO-2014165070-A1 SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10183953-B2 Substituted 2-azabicycles and their use as orexin receptor modulators HCRTR2, HCRTR1, NPY2R HCRTR2 1/4885HCRTR1 2/4885
US-20160052939-A1 SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS HCRTR2, HCRTR1, NPY2R HCRTR2 1/4885HCRTR1 2/4885
US-20170204096-A1 Substituted 2-Azabicycles And Their Use As Orexin Receptor Modulators HCRTR2, HCRTR1, NPY2R HCRTR2 1/4885HCRTR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.